WhatsApp
backNews Article

DCX Systems Fully Utilizes Rs. 400 Crore IPO Funds with Board-Approved Reallocation and Timeline Extension

CARE Ratings confirms no unutilized IPO proceeds as of September 30, 2026; fund use revised with shareholder consent

DCX Systems Limited has fully utilized the Rs. 400 crore raised through its Initial Public Offering (IPO). Following shareholder approval, the company reallocated funds between subsidiary investment and general corporate purposes, and extended the utilization timeline for general corporate purposes until fiscal year 2029. Monitoring agency CARE Ratings reported no deviations beyond approved revisions or unutilized IPO proceeds as of September 30, 2026.

11 Nov 2026|DCXINDIA-2.70%
DCX Systems LimitedDCXINDIALegal / Regulatory

DCX Systems Limited

Legal / Regulatory

DCX Systems Limited has completed the full utilization of the Rs. 400 crore raised from its IPO by September 30, 2026, following fund reallocation approved by shareholders and timeline extension for certain expenditures.

The company raised Rs. 400 crore through a public fresh issue of 1,93,23,671 equity shares during October 31 to November 2, 2022.

Originally, the IPO proceeds were allocated for repayment of borrowings, funding working capital, capital expenditure including investment in subsidiary Renal Advanced Systems Private Limited (RASPL), and general corporate purposes.

The fund allocation was modified with shareholder approval obtained through postal ballot on May 6, 2024, reducing planned investment in RASPL from Rs. 44.88 crore to Rs. 19.80 crore, and increasing the general corporate purpose allocation from Rs. 58.15 crore to Rs. 83.23 crore.

The purpose of the investment in the subsidiary was revised from capital expenditure to loan repayment.

The timeline for utilizing the general corporate purpose funds was extended by board resolution on February 12, 2026, until fiscal year 2029, due to delays compared to the originally expected timeline of March 2026 for this usage segment, although overall IPO proceeds have been fully utilized as of September 30, 2026, as confirmed by CARE Ratings Limited, the appointed Monitoring Agency.

Highlights

  • Full utilization of Rs. 400 crore IPO proceeds by September 30, 2026.
  • Shareholders approved fund reallocation on May 6, 2024, reducing subsidiary investment and increasing general corporate purpose funds.
  • Purpose of subsidiary investment changed to loan repayment from capital expenditure.
  • Timeline for utilizing general corporate purpose funds extended to fiscal year 2029 by board resolution.
  • No deviations from approved utilization beyond authorized changes.
  • Monitoring Agency CARE Ratings Limited issued the utilization report confirming completion.

Key Data Snapshot

IPO proceeds raisedRs. 400.00 crore
Number of shares issued1,93,23,671 equity shares
Original investment in subsidiary RASPLRs. 44.88 crore
Revised investment in subsidiary RASPLRs. 19.80 crore
General corporate purpose allocation (original)Rs. 58.15 crore
General corporate purpose allocation (revised)Rs. 83.23 crore
Expected IPO fund utilization timeline for GCP (original)March 2026
Extended IPO fund utilization timeline for GCPFiscal Year 2029
Monitoring agency report dateSeptember 30, 2026
Date of shareholder postal ballot approvalMay 6, 2024

What happened

  • DCX Systems raised Rs. 400 crore through a public fresh issue in late 2022.
  • The company has fully utilized all IPO proceeds by September 30, 2026.
  • Monitoring agency CARE Ratings Limited confirmed no unutilized funds remained as of this date.

Key details

  • The original offer included investment in subsidiary Renal Advanced Systems Private Limited and general corporate purposes.
  • Shareholder approval was obtained for reallocating funds, notably reducing subsidiary investment and increasing general corporate purposes.
  • The intended subsidiary investment purpose changed from capital expenditure to loan repayment.
  • Timeline for spending general corporate purpose funds was extended to fiscal year 2029 from an original target of March 2026.
  • The company provided the required Monitoring Agency reports per SEBI regulations until full utilization was confirmed.

Regulatory and governance context

  • The monitoring agency report is submitted as per SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2015.
  • No deviations beyond those approved by shareholders were noted in the period ending September 30, 2026.
  • The monitoring agency report is based on information provided by the company and is not an independent audit.

More News on Legal / Regulatory

View all

Latest corporate announcements and market updates in Legal / Regulatory.

View all news
DCX Systems Fully Utilizes Rs. 400 Crore IPO Funds with | Stockk News